Tag: Cancer Drugs
-
Opinion: Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.
[ad_1] A big part of investing in biotech is owning takeover names. The quick gains offset a lot of mistakes. Having a biotech stock get bought out simplifies the “sell” decision, too. Lately, though, biotech investors have been far less enthusiastic about takeover prospects. The Federal Trade Commission (FTC) has cast a shadow over the…
-
AstraZeneca says disappointed with FDA Lynparza vote outcome
[ad_1] AstraZeneca PLC said Tuesday it was disappointed with the outcome of the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee vote on its Lynparza cancer treatment in conjunction with abiraterone and prednisone. The Anglo-Swedish pharmaceutical company AZN UK:AZN said the committee, or ODAC, recognized the treatment’s favorable risk profile but voted 11 to…
-
Merck’s $10.8 billion takeover of Prometheus gives it a foothold in immunology
[ad_1] Merck & Co.’s $10.8 billion acquisition of Prometheus Biosciences Inc., which it announced Sunday, is a strategic positive that will help the drug company diversify its portfolio and reduce the risk of an overreliance on its cancer drug Keytruda, analysts said Monday. San Diego, Calif.-based Prometheus RXDX, +69.34% is a clinical-stage biotechnology company focusing…
-
Moderna, Merck combo cancer-vaccine treatment shows ‘significant’ promise
[ad_1] A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday. About 79% of melanoma patients in a 157-person trial who were treated with Moderna’s personalized mRNA-4157 (V940) therapy in combination with…